Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down – Time to Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $34.65, but opened at $33.27. Collegium Pharmaceutical shares last traded at $34.3540, with a volume of 130,572 shares.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on COLL. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Weiss Ratings lowered Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Collegium Pharmaceutical Stock Down 0.4%

The business has a fifty day simple moving average of $34.11 and a 200 day simple moving average of $40.16. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of 16.44 and a beta of 0.74. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. The business had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.49 earnings per share. As a group, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the business. Group One Trading LLC acquired a new stake in shares of Collegium Pharmaceutical in the fourth quarter valued at $28,000. Caitong International Asset Management Co. Ltd lifted its stake in Collegium Pharmaceutical by 205.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 427 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in Collegium Pharmaceutical during the 4th quarter worth about $61,000. PNC Financial Services Group Inc. boosted its holdings in Collegium Pharmaceutical by 42.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 318 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.